Results 21 to 30 of about 37,073 (238)

Fibroblast growth factor receptor 2 (FGFR2) is required for corneal epithelial cell proliferation and differentiation during embryonic development. [PDF]

PLoS ONE, 2015
Fibroblast growth factors (FGFs) play important roles in many aspects of embryonic development. During eye development, the lens and corneal epithelium are derived from the same surface ectodermal tissue.
Jinglin Zhang, Dinesh Upadhya, Lin Lu, Lixing W Reneker   +3 more
doaj   +2 more sources

Biomechanical strain patterns in Meckel's cartilage underlie mandibular variation in FGFR2 mouse models. [PDF]

Anat Rec (Hoboken)
Abstract Sequence variations in fibroblast growth factor receptor 2 (FGFR2) are associated with craniosynostosis syndromes, disrupting craniofacial development, yet early mandibular alterations remain poorly characterized. This study examined Meckel's cartilage (MC) and mandibular morphology in mouse models of Apert (Fgfr2+/P253R) and Crouzon ...
Foster FR, Freire A, Rossi AC, Wilson J, Richtsmeier JT, Kawasaki K, Prado FB, Perrine SMM.   +7 more
europepmc   +2 more sources

FGFR2 Inhibition in Cholangiocarcinoma

Annual Review of Medicine, 2023
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder carcinoma.
Arndt, Vogel, Oreste, Segatto, Albrecht, Stenzinger, Anna, Saborowski   +3 more
openaire   +2 more sources

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas

Cell & Bioscience, 2023
Background Except for gene fusions, FGFR2 genetic alterations in intrahepatic cholangiocarcinomas (ICCs) have received limited attention, leaving patients harboring activating FGFR2 gene mutations with inadequate access to targeted therapies ...
Xiaohong Pu, Liang Qi, Jia Wu Yan, Zihe Ai, Ping Wu, Fei Yang, Yao Fu, Xing Li, Min Zhang, Beicheng Sun, Shen Yue, Jun Chen   +11 more
doaj   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

Journal of Translational Medicine, 2021
Background Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no ...
Yue Wang, Tao Shi, Xuan Wang, Jinwei Hu, Lixia Yu, Qin Liu, Nandie Wu, Baorui Liu, Jia Wei   +8 more
doaj   +1 more source

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma

Cancer Treatment and Research Communications, 2022
According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma.
Chunye Huang, Qin Wen, Jingyi Chen, Hongguang Zhong, Xiaojun Xiang, Jianping Xiong, Jun Deng   +6 more
openaire   +3 more sources

FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. [PDF]

PLoS ONE, 2014
Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene ...
Anjili Mathur, Christopher Ware, Lenora Davis, Adi Gazdar, Bo-Sheng Pan, Bart Lutterbach   +5 more
doaj   +1 more source

CRISPR/Cas9 mediated FGFR2 down-regulation alleviatespremature closure of cranial suture in an Apert syndromemouse model

生物医学转化, 2021
Apert syndrome (AS) is characterized by synostosis of coronal sutures, midfacial hypoplasia,abnormity of brain, syndactyly of hands and feet. Majority of AS is caused by gain-of-function mutation of fibro‐blast growth factor receptor 2 (FGFR2).
Luo Fengtao, Xie Yangli, Li Can, Tan Qiaoyan, Du Xiaolan, Chen Lin   +5 more
doaj   +1 more source